Welcome to our dedicated page for Asensus Surgical news (Ticker: ASXC), a resource for investors and traders seeking the latest updates and insights on Asensus Surgical stock.
Asensus Surgical, Inc. (NYSE American: ASXC) is a trailblazing medical device company that enhances minimally invasive surgery through digital laparoscopy. The company's flagship product, the Senhance® Surgical System, is the first machine vision system used in robotic surgery. It leverages augmented intelligence, connectivity, and robotics to address clinical, cognitive, and economic challenges in surgery.
Headquartered in Research Triangle Park, North Carolina, Asensus Surgical focuses exclusively on the research, development, and sale of medical device robotics aimed at improving surgical outcomes. The company's cutting-edge technology includes the Intelligent Surgical Unit™ that brings augmented intelligence into the operating room. One of its latest innovations is the LUNA™ Surgical System, a next-generation robotic and instrument system under development.
Committed to global healthcare improvements, Asensus Surgical has expanded its reach with the Senhance System now available in the US, EU, Japan, Russia, and select other countries. The system has recently been adopted by Nagoya University Hospital in Japan, dedicated to pediatric procedures. This marks a significant milestone, as the Senhance System offers specialized instrumentation and advanced clinical intelligence, aimed at reducing invasiveness and increasing precision in pediatric surgery.
In a recent strategic move, Asensus Surgical entered into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG. This merger, valued at $0.35 per share, is anticipated to enhance KARL STORZ's portfolio and market presence, particularly in the robotic surgical market. The transaction has been unanimously approved by Asensus’ Board of Directors and is expected to close during the third quarter of 2024.
Asensus Surgical continues to be driven by collaboration and human ingenuity, striving to make surgery more accessible and predictable while delivering consistently superior outcomes. For more detailed information, visit www.asensus.com.
Asensus Surgical (NYSE American: ASXC) announced its 510(k) submission to the FDA for enhanced capabilities of the Intelligent Surgical Unit™ (ISU™). This development aims to improve the Senhance Surgical System through augmented intelligence, enabling surgeons to gather real-time data during procedures. CEO Anthony Fernando emphasizes that these advancements are pivotal for digital surgery performance. The ISU currently facilitates machine vision-driven control, enhancing surgical precision and decision-making, which could lead to improved surgical outcomes.
Asensus Surgical, Inc. (ASXC) has announced its participation in the Ladenburg Thalmann 2021 Virtual Healthcare Conference. Scheduled for July 14, 2021, at 8:30 AM ET, the presentation will feature CEO Anthony Fernando and CFO Shameze Rampertab. A live webcast will be accessible through the company's investor relations page, with replays available for 90 days. Asensus is focused on Performance-Guided Surgery, leveraging its Senhance® Surgical System to improve surgical outcomes and reduce variability.
Asensus Surgical, Inc. (NYSE American: ASXC) announced the adjournment of its 2021 Annual Meeting of Stockholders to July 22, 2021. The meeting will now be held virtually, allowing retail stockholders more time to consider and vote on the proposals outlined in the Proxy Statement. Stockholders are encouraged to vote promptly, whether via phone or Internet, using their proxy control number. Proxies submitted prior to the adjournment will be valid and counted at the upcoming meeting.
Asensus Surgical (ASXC) has initiated its Senhance® Surgical System program at Inselspital, University Hospital Bern, Switzerland, marking the second agreement with European hospitals in 2021. This innovative digital laparoscopic platform employs augmented intelligence to enhance surgical performance and patient outcomes. The hospital, the largest university group in Switzerland, will implement the Senhance system in daily practice and assess its clinical utility. Asensus aims to redefine surgery standards through this technology, which is now available for sale in multiple countries.
Asensus Surgical, Inc. (ASXC) announced its inclusion in the Russell 2000® and Russell Microcap® Indexes, effective June 28, 2021. This follows the annual reconstitution of the Russell indexes, which rank stocks by market capitalization. The company highlighted that this milestone may enhance its visibility and appeal to investors, with CEO Anthony Fernando expressing optimism about the benefits for stockholders. The Russell indexes are used for benchmarking by a significant amount of institutional assets, totaling approximately $10.6 trillion.
Asensus Surgical (NYSE American: ASXC) announced the adjournment of its 2021 Annual Meeting of Stockholders, originally set for June 3, 2021, to June 29, 2021. The adjournment aims to provide retail stockholders more time to consider and vote on key proposals detailed in the Proxy Statement. Stockholders are encouraged to vote, utilizing their proxy control number. Proxies already submitted remain valid. The Company emphasizes the importance of stockholder participation as it continues to advance its innovative approach to Performance-Guided Surgery.
Asensus Surgical, a medical device company listed on NYSE American as ASXC, announced that its CEO Anthony Fernando and CFO Shameze Rampertab will participate in the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. Their presentation will be accessible on-demand starting at 8:00 am ET on the same day. This event aims to showcase Asensus's efforts in pioneering Performance-Guided Surgery through innovations like the Senhance Surgical System, enhancing surgical outcomes and addressing healthcare challenges.
Asensus Surgical, Inc. (ASXC) reported a strong start to 2021, achieving revenue of $2.1 million in Q1, significantly up from $0.6 million in the same period last year. The quarter saw operational advancements, including FDA 510(k) submissions and receiving CE Mark for the Intelligent Surgical Unit™. Additionally, the company secured a total of $111 million in equity financings, extending its cash runway into 2024. Despite a net loss of $17.3 million, Asensus is optimistic about the future, anticipating the installation of 10-12 new Senhance systems by year-end.
Asensus Surgical (ASXC) has announced a lease agreement with LAKUMED hospitals for its Senhance Surgical System, which will be utilized at the Landshut-Achdorf hospital near Munich, Germany. This marks a significant expansion as Germany becomes a key market for the Senhance platform, now the largest in Europe by users and surgeries. The Senhance system offers advanced capabilities such as haptic feedback and 3 mm instruments, enhancing minimally invasive surgery. LAKUMED aims to lead in integrating advanced technologies and skilled surgical practices for patient care.
Asensus Surgical, Inc. (NYSE American: ASXC) will release its Q1 2021 financial and operating results after market close on May 11, 2021. A conference call is scheduled for 4:30 p.m. ET, which will also be available via webcast. The company focuses on digitizing the surgeon-patient interface through its Senhance® Surgical System, aimed at enhancing surgical outcomes with intelligent technology. This includes machine vision and deep learning to address current surgical challenges. The system is currently available for sale in multiple countries including the US, EU, and Japan.
FAQ
What is the current stock price of Asensus Surgical (ASXC)?
What is the market cap of Asensus Surgical (ASXC)?
What does Asensus Surgical, Inc. do?
Where is Asensus Surgical headquartered?
What is the Senhance® Surgical System?
What is the latest innovation from Asensus Surgical?
In which regions is the Senhance® Surgical System available?
Has Asensus Surgical recently partnered with any hospitals?
What is the merger agreement with KARL STORZ about?
When is the merger with KARL STORZ expected to close?
Will Asensus Surgical continue to be publicly traded after the merger?
How can I learn more about Asensus Surgical's products?
